Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript
AKCA earnings call for the period ending December 31, 2018.
Akcea Therapeutics, Inc.
AKCA
$28.16
$0.82
3.0%
BATS BZX Real Time Price as of March 26, 2019, 12:43 p.m.
View Interactive AKCA Charts
Akcea Therapeutics, Inc.
News & Analysis: Akcea Therapeutics, Inc.
All
Market Moves
Earnings
Here's Why Ionis Pharmaceuticals Rose 12.9% in September
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?
A surprise rejection is a major setback for both partners, but not the end of the line.
Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today
The FDA gives a thumbs down to their triglyceride-lowering drug Waylivra.
Akcea Therapeutics Soars as It Readies Its First Drug Launch
But the real opportunity may be with Ionis Pharmaceuticals.
3 Biotech Stocks With Major Catalysts Incoming
Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.
Why Akcea Therapeutics Rocketed Higher Today
An FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.
3 Small-Cap Biotech Stocks With Big Catalysts in May
Key events will make May a month to remember or forget for these fledgling drugmakers.
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these sizzling biotech stocks keep the momentum going?
Why Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is Dropping
News of a major transaction between these two companies sends their stock prices in opposite directions.
